Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333917 | 0.86 | ALDH1A1 (0.68) | ALDH1A1HSD17B10PTGS2L3MBTL1PDE4A | |
| SCHEMBL18342130 | 0.85 | ALDH1A1 (0.65) | ALDH1A1HSD17B10PTGS2L3MBTL1PDE4A | |
| SCHEMBL29539416 | 0.83 | ALDH1A1 (0.94) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL30985618 | 0.83 | ALDH1A1 (0.94) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 | |
| Sulfuric Acid SCHEMBL28101132 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HSD17B10PTGS2L3MBTL1CA12 | |
| Hydrochloric Acid SCHEMBL15571781 | 0.81 | ALDH1A1 (0.90) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29427302 | 0.81 | ALDH1A1 (0.90) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 | |
| Methylamine SCHEMBL9562971 | 0.81 | ALDH1A1 (0.90) | ALDH1A1HSD17B10PTGS2L3MBTL1PDE4A | |
| SCHEMBL25981 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL28465796 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111732573-B | Quinolone acid-aminopyrimidine compound and preparation method and application thereof | 复旦大学 | 2022-09-16 | — | — | CN | claimed |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2021-10-28 | — | — | US | claimed |
| EP-3837245-A1 | SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| CN-112888677-A | Substituted 4-amino-1H-imidazo [4,5-c ] quinoline compounds and improved process for their preparation | 先天肿瘤免疫公司 | 2021-06-01 | — | — | CN | claimed |
| CN-111732573-A | Quinolone acid-aminopyrimidine compound and preparation method and application thereof | 复旦大学 | 2020-10-02 | — | — | CN | claimed |
| WO-2020037094-A1 | SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| CN-122059998-A | Palladium complex and preparation method and application thereof | 云南贵金属实验室有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORP (US) | 2026-04-23 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | CELGENE CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4662207-A2 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| CN-106661018-B | Pyrrolo- [2,3-C] pyridine as neurofibrillary tangles imaging agent | 默沙东公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | ALDH1A1 277/4885HSD17B10 910/4885PTGS2 3038/4885 |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | IRAK3, IRAK2, IRAK1 | ALDH1A1 1519/4885HSD17B10 2414/4885PTGS2 3772/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | ALDH1A1 259/4885HSD17B10 875/4885PTGS2 2982/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | ALDH1A1 277/4885HSD17B10 910/4885PTGS2 3038/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ALDH1A1 3566/4885HSD17B10 4197/4885PTGS2 4809/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | ALDH1A1 259/4885HSD17B10 875/4885PTGS2 2982/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | ALDH1A1 326/4885HSD17B10 49/4885PTGS2 775/4885 |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | PSME2, MKRN3, RPS6KA2 | ALDH1A1 3760/4885HSD17B10 1399/4885PTGS2 1444/4885 |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | ALDH1A1 3065/4885HSD17B10 4099/4885PTGS2 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.